AbbVie Inc. closed $6.12 short of its 52-week high ($199.95), which the company reached on September 3rd.
AbbVie ABBV announced that the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended approving the ...
After spinning off from Abbott Labs in 2013, biopharmaceutical giant AbbVie had to establish its own culture. Here's how the ...
North Chicago, Illinois Monday, September 23, 2024, 13:00 Hrs [IST] ...
This includes rimegepant, which is sold by U.S. pharma giant Pfizer under the brand name Vydura, and ubrogepant, sold as ...
The 13 drugs most likely to be chosen for CMS negotiations, according to the study: Ozempic, Rybelsus and Wegovy (semaglutide): Novo Nordisk's treatment for Type 2 diabetes and weight management.
14h
BTIG analyst Ryan Zimmerman maintained a Buy rating on Glaukos (GKOS – Research Report) yesterday and set a price target of $139.00. Ryan ...
More than 75% of the cohort started a TNF inhibitor during the selected time frame. For the rest, JAK inhibitors were the ...
Osteopenia was originally a qualitative term denoting bone that appeared to be less dense on radiographs. Since 1994, it has ...
Developer Jimmy Banks said Bare Arms Brewing is only one of multiple attractions he has in mind at the Robinson site.
REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in Chardan's 8th Annual Genetic Medicines Conference on Monday, September 30, 2024.
MedPage Today on MSN8h
McDonald Criteria Revisions Signal Shift Toward MS as a Biologically Based DiseaseThe revisions signal a shift toward looking at MS more as a biologically based disease, noted Xavier Montalban, MD, PhD, of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback